12:40 PM EDT, 08/25/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price to $72 from $54 based on recent market movements and a 7.9x multiple of our 2026 sales estimate. This is a small premium to GH's historical forward average due to our view of a strengthening sales growth outlook. We maintain our 2025 and 2026 EPS estimates of -$1.87 and -$1.63, respectively. We forecast approximately 25% sales growth in 2025, at the upper end of GH's guidance, with oncology revenue growing approximately 20% year-over-year (vs. our prior forecast of 18%) backed by stronger-than-expected Guardant360 Liquid and Reveal volumes as well as higher oncology volumes (+27% Y/Y growth). We anticipate the biopharma and data business will perform well throughout 2025, with a revenue growth rate in the mid teens. We continue to see accelerating adoption of liquid biopsy technology and expanding reimbursement coverage supporting the strong top-line growth trajectory.